Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)

Phase 2 Completed 11 enrolled Icahn School of Medicine at Mount Sinai

RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this crossover trial is to investigate whether atomoxetine (versus placebo) improves memory function in persons with memory deficits due to multiple sclerosis.

Timeline

Start: 2017-03-16
Primary completion: 2018-06-11
Completion: 2018-06-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atomoxetine	Other / unclassified	80 mg	Oral

Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)

Summary

Timeline

Drugs

Indications